Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Lotze

Showing results (51-60 of 299) with videos related to

Pageof 30
Sort By:
Cancer Research|August 15, 1987
Separation and functional studies of the human lymphokine-activated killer cellK Roberts, M T Lotze, S A Rosenberg
Cancer Gene Therapy|June 1, 1995
Genetically marking human cells--results of the first clinical gene transfer studiesQ Cai, J T Rubin, M T Lotze
Cytokine & Growth Factor Reviews|August 28, 1998
FLT3: receptor and ligand. Biology and potential clinical applicationM R Shurin, C Esche, M T Lotze
Journal of Molecular Medicine (Berlin, Germany)|July 1, 1997
Gene-based strategies for the immunotherapy of cancerT Tüting, W J Storkus, M T Lotze
Scandinavian Journal of Immunology|February 12, 2008
Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cellsJ Vakkila, R A Demarco, M T Lotze
Cancer|December 1, 1988
Colonic perforation. An unusual complication of therapy with high-dose interleukin-2D Schwartzentruber, M T Lotze, S A Rosenberg
The Journal of Experimental Medicine|December 1, 1988
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanomaY Kawakami, S A Rosenberg, M T Lotze
Current Opinion in Molecular Therapeutics|March 16, 2001
The use of dendritic cells for cancer vaccinationC Esche, M R Shurin, M T Lotze
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4Y Kawakami, G P Haas, M T Lotze
Gene Therapy|January 19, 2000
Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor modelsK Hiroishi, T Tüting, H Tahara, et al.
Pageof 30

Showing results (51-60 of 299) with videos related to

Sort By:
Pageof 30
Cancer Research|August 15, 1987
Separation and functional studies of the human lymphokine-activated killer cellK Roberts, M T Lotze, S A Rosenberg
Cancer Gene Therapy|June 1, 1995
Genetically marking human cells--results of the first clinical gene transfer studiesQ Cai, J T Rubin, M T Lotze
Cytokine & Growth Factor Reviews|August 28, 1998
FLT3: receptor and ligand. Biology and potential clinical applicationM R Shurin, C Esche, M T Lotze
Journal of Molecular Medicine (Berlin, Germany)|July 1, 1997
Gene-based strategies for the immunotherapy of cancerT Tüting, W J Storkus, M T Lotze
Scandinavian Journal of Immunology|February 12, 2008
Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cellsJ Vakkila, R A Demarco, M T Lotze
Cancer|December 1, 1988
Colonic perforation. An unusual complication of therapy with high-dose interleukin-2D Schwartzentruber, M T Lotze, S A Rosenberg
The Journal of Experimental Medicine|December 1, 1988
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanomaY Kawakami, S A Rosenberg, M T Lotze
Current Opinion in Molecular Therapeutics|March 16, 2001
The use of dendritic cells for cancer vaccinationC Esche, M R Shurin, M T Lotze
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1993
Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4Y Kawakami, G P Haas, M T Lotze
Gene Therapy|January 19, 2000
Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor modelsK Hiroishi, T Tüting, H Tahara, et al.
Pageof 30